CVS Health Corporation is rated a Buy with a strong turnaround driving industry-leading results. Learn more about CVS stock ...

CVS Health’s narrative has shifted with a slightly higher fair value estimate, nudging from about $91.50 to roughly $92.40 ...

The healthcare giant expects its turnaround efforts to pay off as it raised its full-year outlook and expects that momentum ...

Fintel reports that on December 12, 2025, Bernstein maintained coverage of CVS Health (NYSE:CVS) with a Market Perform ...

CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.

It’s part of a larger battle between Louisiana officials and big health care companies over prescription drug prices.

CVS Health raises its 2025 revenue outlook as Bank of America highlights stronger margins, new tech investments, and momentum ...

Fintel reports that on December 10, 2025, Baird maintained coverage of CVS Health (NYSE:CVS) with a Outperform recommendation ...

In addition to the updates for 2025, CVS offered its first look at expected earnings for 2026. The company said it ...

Today at its 2025 Investor Day, CVS Health® (NYSE: CVS) (the "Company") will launch its strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and ...

On the same day, RBC Capital maintained its Outperform rating and $93 price target on CVS Health Corporation (NYSE:CVS) ...